AI companies are running virtual drug trials in an effort to improve the success rate of human clinical studies. Novartis’ once‑touted del-desiran missed its target in a late-stage trial, sending the stock down 11% in a single session and wiping out $30 billion in market value. Takeda’s head of research said the TYK2 target was identified through human genetics analysis, and machine learning was used to refine the structure of a once-daily oral pill.

Caribou Biosciences said it will shut down after it was unable to raise enough money to support a late-stage clinical trial of its CAR-T therapy for lymphoma. The Berkeley, California-based biotech, which traces its roots to Nobel laureate Jennifer Doudna’s CRISPR research lab, will stop clinical development of two CRISPR-based CAR-T programs, including vispa-cel for advanced B-cell non-Hodgkin lymphoma. The company had finalized a Phase 3 trial design with the U.S. Food and Drug Administration, but financing the study proved too difficult, STAT reported.

A selloff in Europe’s bond market is making investors more cautious toward higher-risk sovereign debt. France and Italy have seen yields climb on worsening fiscal outlooks, while demand has shifted toward German bonds as a safe haven. France plans to issue a record €340 billion of bonds in 2027, and Italy’s debt-to-GDP ratio is expected to become the highest in the European Union. Analysts say the latest bond-market turbulence could push the euro down toward $1.10.

At Token2049, Tom Lee said BitMine has set a 5% “hard cap” on its ETH holdings and will stop buying once that level is reached. He added that the firm needs to acquire about another 100,000 ETH to get to 5%. Lee said the cap is intended to optimize shareholder value. The comments indicate BitMine’s room to increase its ETH position is nearing its limit, though it has not reached the cap yet.

Micron Technology’s data center SSD revenue now accounts for more than 70% of its NAND flash revenue. Enterprise SSD demand is expected to grow by more than 80% this year. An analyst reiterated a Buy rating on Micron with a $1,500 price target, implying about 41% upside from current levels.

Sberbank, Russia’s largest bank, has received official approval to act as a crypto-asset custodian and plans to launch products tied to Bitcoin, Ethereum and USDT. The move marks the first time a Russian state-owned financial institution has entered digital-asset services directly, offering domestic investors a regulated channel to hold and trade cryptocurrencies. The product lineup focuses on major crypto assets and is expected to boost market participation and compliance standards.

Marvell shares rose 5.8% on October 6 after the company laid out long-term revenue expectations at its Investor Day. Jefferies analyst Blayne Curtis raised his price target to $450 from $325 and reiterated a Buy rating. He pointed to growth potential in Marvell’s interconnect business and custom chips, particularly tied to AI inference.

Moderna (MRNA) fell 7.75% to $187.46 on October 6, 2026, as Citi's valuation downgrade and a reversal from pre-ESMO melanoma expectations weighed on the shares. This draft examines the daily setup, event risks and technical levels that could shape the next move.